SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?


To: Pseudo Biologist who wrote (351)11/16/1999 8:25:00 PM
From: Trey Yon  Read Replies (1) | Respond to of 666
 
Coulter beginning to remind me painfully of IPIC,
Glenn Cooper is the only CEO I've ever encountered who was better at getting drugs PULLED off the market & out of Ph III trials. Redux pulled from market, Bextra Ph III study failed July 99; CerAxon Ph III results granted Fast Track review only to have to go back & do another year or two of study, while lawyers & research rapidly bled IPIC dry.

Good thing CLTR has a pretty good cash pile.